Happy New Year! Please be advised that in-transit patient samples will be held by the carrier on Jan. 1, and received by our lab the next day. Kit orders placed on Dec. 31 and Jan. 1 will be sent on Jan. 2. Our genetic counseling services, client services, and billing services will be unavailable on Jan. 1; please leave us a message at 888-729-1206 or support@genedx.com and we will respond when we return.
Chief Executive Officer
Katherine Stueland has dedicated her career to transforming healthcare through leadership at patient-centric businesses. Her career has spanned supporting the FDA approval of several rare disease therapeutics, the first protease inhibitor for HIV/AIDS and the first cancer immunotherapy, all of which were made possible by the powerful voices of patient advocates. Over the past decade, Katherine has been a central figure in moving healthcare toward widespread use of genomic information to improve the accuracy and effectiveness of the diagnosis of rare disease and cancer.
In June 2021, Katherine became the President and CEO of GeneDx (Nasdaq: WGS), a company that emerged from the National Institutes of Health and today is at the forefront of transforming healthcare through genomic insights with a mission to end the diagnostic odyssey. GeneDx delivers personalized and actionable health insights to inform diagnosis, direct treatment and drug discovery. Katherine led the company through a massive company transformation, focusing the business on its industry-leading exome and genome testing and interpretation products, fueled by one of the world’s largest, rare disease data sets. Under her leadership, GeneDx has nearly tripled the number of patients it’s been able to sequence, completing nearly 700,000 exomes and genomes while at the same time leading the company toward profitability and a market cap of more than $1 billion.
Katherine’s career is rooted in bringing transformational technologies to market and crafting strategies to evolve a new standard of care to keep people healthier and living longer lives. Prior to GeneDx, Katherine was the Chief Commercial Officer of Invitae , a medical genetics company where she established the corporate brand as the company evolved from a private to a public entity.
In 2023, Katherine was recognized as one of the most influential people in biotech by Fierce Pharma and was a runner up for the most influential leaders by Modern Healthcare. She serves on the JED Foundation Leadership Council, a nonprofit organization that works to prevent suicide and protect the emotional health of young adults and teens as part of her lifetime commitment to help improve mental health and fitness. Katherine is also passionate about mentoring women on effective leadership, creating human-centric business strategies, and generating career opportunities for emerging leaders. Katherine graduated from Miami University in Oxford, Ohio, in 1997 with a bachelor’s degree in Science and English Literature.
